Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD

Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD

Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during...

Full description

Bibliographic Details
Main Authors: Michael P. Liesen, Megan L. Noonan, Pu Ni, Rafiou Agoro, Julia M. Hum, Erica L. Clinkenbeard, John G. Damrath, Joseph M. Wallace, Elizabeth A. Swallow, Matthew R. Allen, Kenneth E. White
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Physiological Reports
Subjects:
CKD
ferric citrate
GF23
iron
kidney
klotho
Online Access:https://doi.org/10.14814/phy2.15307

Internet

https://doi.org/10.14814/phy2.15307

Similar Items